Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia

Schizophrenia Research

Volumn 133, Issue 1-3, 2011, Pages 82-90

  Seese, Ronald R ^a   O'Neill, Joseph ^a   Hudkins, Matthew ^a   Siddarth, Prabha ^a   Levitt, Jennifer ^a   Tseng, Ben ^a   Wu, Keng Nei ^a   Caplan, Rochelle ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Childhood onset schizophrenia; Choline compounds; Magnetic resonance spectroscopy; N acetyl aspartate; Thought disorder

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID;

ADOLESCENT; AMINO ACID BRAIN LEVEL; ARTICLE; BRAIN METABOLISM; CHILD; CHILD PSYCHIATRY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INFERIOR TEMPORAL GYRUS; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; SCHOOL CHILD; SPEECH ANALYSIS; SUPERIOR TEMPORAL GYRUS; THOUGHT DISORDER;

ADOLESCENT; ANALYSIS OF VARIANCE; ASPARTIC ACID; BRAIN; CHILD; CHOLINE; COGNITION DISORDERS; CREATINE; DIPEPTIDES; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROPSYCHOLOGICAL TESTS; PHOSPHOCREATINE; PROTONS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA, CHILDHOOD; STATISTICS, NONPARAMETRIC;

EID: 81955162942     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.07.011     Document Type: Article

References (82)

1. Assaf M., Rivkin P., Kuzu C., Calhoun V., Kraut M., Groth K., Yassa M., Hart J.J., Pearlson G. Abnormal object recall and anterior cingulate overactivation correlate with formal thought disorder in schizophrenia. Biol. Psychiatry 2006, 59(5):452-459.
2. Bartha R., al-Semaan Y.M., Williamson P.C., Drost D.J., Malla A.K., Carr T.J., Densmore M., Canaran G., Neufeld R.W. A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol. Psychiatry 1999, 45(11):1403-1411.
3. Bayer T.A., Buslei R., Havas L., Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 1999, 271(2):126-128.
4. Bergeron R., Coyle J., Tsai G., Greene R. NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 2005, 30(1):7-16.
5. Bertolino A., Weinberger D. Proton magnetic resonance spectroscopy in schizophrenia. Eur. J. Radiol. 1999, 30(2):132-141.
6. Bertolino A., Nawroz S., Mattay V., Barnett A., Duyn J., Moonen C., Frank J., Tedeschi G., Weinberger D. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry 1996, 153(12):1554-1563.
7. Bertolino A., Kumra S., Callicott J., Mattay V., Lestz R., Jacobsen L., Barnett I., Duyn J., Frank J., Rapoport J., Weinberger D. Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry 1998, 155(10):1376-1383.
8. Bertolino A., Knable M.B., Saunders R.C., Callicott J.H., Kolachana B., Mattay V.S., Bachevalier J., Frank J.A., Egan M., Weinberger D.R. The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biol. Psychiatry 1999, 45(6):660-667.
9. Bertolino A., Callicott J.H., Mattay V.S., Weidenhammer K.M., Rakow R., Egan M.F., Weinberger D.R. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry 2001, 49(1):39-46.
10. Bertolino A., Sciota D., Brudaglio F., Altamura M., Blasi G., Bellomo A., Antonucci N., Callicott J.H., Goldberg T.E., Scarabino T., Weinberger D.R., Nardini M. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am. J. Psychiatry 2003, 160(3):483-489.
11. Blanton R., Levitt J., Peterson J., Fadale D., Sporty M., Lee M., To D., Mormino E., Thompson P., McCracken J., Toga A. Gender differences in the left inferior frontal gyrus in normal children. Neuroimage 2004, 22(2):626-636.
12. Block W., Bayer T.A., Tepest R., Traber F., Rietschel M., Muller D.J., Schulze T.G., Honer W.G., Maier W., Schild H.H., Falkai P. Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neurosci. Lett. 2000, 289(2):147-151.
13. Borofsky L., McNealy K., Siddarth P., Wu K., Dapretto M., Caplan R. Semantic processing and thought disorder in childhood-onset schizophrenia: Insights from fMRI. J. Neuroling Res. 2010, 23(3):204-222.
14. Braus D.F., Ende G., Weber-Fahr W., Demirakca T., Henn F.A. Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics: an MRSI study. Pharmacopsychiatry 2001, 34(6):251-253.
15. Braus D.F., Ende G., Weber-Fahr W., Demirakca T., Tost H., Henn F.A. Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur. Neuropsychopharmacol. 2002, 12(2):145-152.
16. Brooks W.M., Hodde-Vargas J., Vargas L.A., Yeo R.A., Ford C.C., Hendren R.L. Frontal lobe of children with schizophrenia spectrum disorders: a proton magnetic resonance spectroscopic study. Biol. Psychiatry 1998, 43(4):263-269.
17. Bustillo J.R., Lauriello J., Rowland L.M., Jung R.E., Petropoulos H., Hart B.L., Blanchard J., Keith S.J., Brooks W.M. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res. 2001, 107(3):135-149.
18. Callicott J.H., Bertolino A., Mattay V., Langheim F., Duyn J., Coppola R., Goldberg T., Weinberger D. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex 2000, 10(11):1078-1092.
19. Caplan R., Dapretto M. Making sense during conversation: an fMRI study. Neuroreport 2001, 12(16):3625-3632.
20. Caplan R., Guthrie D., Fish B., Tanguay P., David-Lando G. The Kiddie Formal Thought Disorder Rating Scale: clinical assessment, reliability, and validity. J. Am. Acad. Child Adolesc. Psychiatry 1989, 28(3):408-416.
21. Caplan R., Guthrie D., Tang B., Komo S., Asarnow R. Thought disorder in childhood schizophrenia: replication and update of concept. J. Am. Acad. Child Adolesc. Psychiatry 2000, 39(6):771-778.
22. Caplan R., Siddarth P., Bailey C., Lanphier E., Gurbani S., Donald Shields W., Sankar R. Thought disorder: a developmental disability in pediatric epilepsy. Epilepsy Behav. 2006, 8(4):726-735.
23. Cecil K.M., Lenkinski R.E., Gur R.E., Gur R.C. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology 1999, 20(2):131-140.
24. Cerullo M., Adler C., Strakowski S., Eliassen J., Nasrallah H., Nasrallah A. Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study. Schizophr. Res. 2007, 97(1-3):294-296.
25. Choe B.Y., Kim K.T., Suh T.S., Lee C., Paik I.H., Bahk Y.W., Shinn K.S., Lenkinski R.E. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad. Radiol. 1994, 1(3):211-216.
26. Coyle J., Tsai G., Goff D. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 2002, 1(2):183-189.
27. Coyle J., Tsai G., Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann. N. Y. Acad. Sci. 2003, 1003:318-327.
28. de Gannes F., Merle M., Canioni P., Voisin P. Metabolic and cellular characterization of immortalized human microglial cells under heat stress. Neurochem. Int. 1998, 33(1):61-73.
29. Deicken R., Zhou L., Corwin F., Vinogradov S., Weiner M.W. Decreased left frontal lobe N-acetylaspartate in schizophrenia. Am. J. Psychiatry 1997, 154(5):688-690.
30. Deicken R., Zhou L., Schuff N., Fein G., Weiner M. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol. Psychiatry 1998, 43(7):483-488.
31. Deicken R., Pegues M., Amend D. Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia. Schizophr. Res. 1999, 37(3):217-223.
32. Demougeot C., Garnier P., Mossiat C., Bertrand N., Giroud M., Beley A., Marie C. N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. J. Neurochem. 2001, 77(2):408-415.
33. Edden R., Pomper M., Barker P. In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. Magn. Reson. Med. 2007, 57(6):977-982.
34. Ende G., Braus D., Walter S., Weber-Fahr W., Soher B., Maudsley A., Henn F. Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophr. Res. 2000, 41(3):389-395.
35. Gochman P.A., Greenstein D., Sporn A., Gogtay N., Keller B., Shaw P., Rapoport J.L. IQ stabilization in childhood-onset schizophrenia. Schizophr. Res. 2005, 77(2-3):271-277.
36. Hagino H., Suzuki M., Mori K., Nohara S., Yamashita I., Takahashi T., Kurokawa K., Matsui M., Watanabe N., Seto H., Kurachi M. Proton magnetic resonance spectroscopy of the inferior frontal gyrus and thalamus and its relationship to verbal learning task performance in patients with schizophrenia: a preliminary report. Psychiatry Clin. Neurosci. 2002, 56(5):499-507.
37. Hall J., Romaniuk L., McIntosh A., Steele J., Johnstone E., Lawrie S. Associative learning and the genetics of schizophrenia. Trends Neurosci. 2009, 32(6):359-365.
38. Heimberg C., Komoroski R.A., Lawson W.B., Cardwell D., Karson C.N. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res. 1998, 83(2):105-115.
39. Holinger D., Shenton M., Wible C., Donnino R., Kikinis R., Jolesz F., McCarley R. Superior temporal gyrus volume abnormalities and thought disorder in left-handed schizophrenic men. Am. J. Psychiatry 1999, 156(11):1730-1735.
40. Jessen F., Scherk H., Traber F., Theyson S., Berning J., Tepest R., Falkai P., Schild H., Maier W., Wagner M., Block W. Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr. Res. 2006, 87(1-3):81-88.
41. Jung R., Brooks W., Yeo R., Chiulli S., Weers D., Sibbitt W.J. Biochemical markers of intelligence: a proton MR spectroscopy study of normal human brain. Proc. Biol. Sci. 1999, 266(1426):1375-1379.
42. Kadota T., Horinouchi T., Kuroda C. Development and aging of the cerebrum: assessment with proton MR spectroscopy. AJNR Am. J. Neuroradiol. 2001, 22(1):128-135.
43. Kaufman J., Birmaher B., Brent D., Rao U., Flynn C., Moreci P., Williamson D., Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36(7):980-988.
44. Kircher T. Neurobiological foundations of thought and language disorder in schizophrenia. Fortschr. Neurol. Psychiatr. 2008, 76(Suppl 1):S24-32.
45. Kircher T., Liddle P., Brammer M., Murray R., McGuire P. Neural correlates of "negative" formal thought disorder. Nervenarzt 2003, 74(9):748-754.
46. Lim K., Adalsteinsson E., Spielman D., Sullivan E., Rosenbloom M., Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch. Gen. Psychiatry 1998, 55(4):346-352.
47. Maier M., Ron M., Barker G., Tofts P. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol. Med. 1995, 25(6):1201-1209.
48. Maudsley A. MR spectroscopic imaging. Brain Mapping: The Methods 2002, 351-378. Academic Press, Amsterdam. A.W. Toga, J.C. Mazziotta (Eds.).
49. McGuire P., Quested D., Spence S., Murray R., Frith C., Liddle P. Pathophysiology of 'positive' thought disorder in schizophrenia. Br. J. Psychiatry 1998, 173:231-235.
50. Mehler C., Warnke A. Structural brain abnormalities specific to childhood-onset schizophrenia identified by neuroimaging techniques. J. Neural Transm. 2002, 109(2):219-234.
51. Molina V., Sanchez J., Reig S., Sanz J., Benito C., Santamarta C., Pascau J., Sarramea F., Gispert J.D., Misiego J.M., Palomo T., Desco M. N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. Schizophr. Res. 2005, 73(2-3):209-219.
52. Molina V., Sanz J., Sarramea F., Luque R., Benito C., Palomo T. No association between dorsolateral prefrontal gray matter deficit and N-acetyl aspartate ratios in schizophrenia. Neuropsychobiology 2006, 54(3):171-178.
53. Molina V., Sanchez J., Sanz J., Reig S., Benito C., Leal I., Sarramea F., Rebolledo R., Palomo T., Desco M. Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder. Eur. Psychiatry 2007, 22(8):505-512.
54. O'Neill J., Tseng P.B., Pagare R., Frew A.J., Tafazoli S., Alger J.R. MRSI Voxel Picker (MVP): software for co-evaluation of structural and spectroscopic information. ISMRM Workshop on Quantitative Spectroscopy 2006, Warrenton, VA.
55. O'Neill J., Levitt J., Caplan R., Asarnow R., McCracken J., Toga A., Alger J. 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia. Neuroimage 2004, 21(4):1781-1789.
56. Pae C.U., Choe B.Y., Joo R.H., Lim H.K., Kim T.S., Yoo S.S., Choi B.G., Kim J.J., Lee S.J., Lee C., Paik I.H., Lee C.U. Neuronal dysfunction of the frontal lobe in schizophrenia. Neuropsychobiology 2004, 50(3):211-215.
57. Passani L., Elkabes S., Coyle J. Evidence for the presence of N-acetylaspartylglutamate in cultured oligodendrocytes and LPS activated microglia. Brain Res. 1998, 794(1):143-145.
58. Pouwels P., Frahm J. Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed. 1997, 10(2):73-78.
59. Provencher S. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001, 14(4):260-264.
60. Rosenbaum P., Rubin D. The central role of the propensity score in observational studies. Biometrika 1983, 70:41-45.
61. Rusch N., Tebartz van Elst L., Valerius G., Buchert M., Thiel T., Ebert D., Hennig J., Olbrich H. Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr. Res. 2008, 99(1-3):155-163.
62. Shattuck D., Sandor-Leahy S., Schaper K., Rottenberg D., Leahy R. Magnetic resonance image tissue classification using a partial volume model. Neuroimage 2001, 13(5):856-876.
63. Shenton M., Kikinis R., Jolesz F., Pollak S., LeMay M., Wible C., Hokama H., Martin J., Metcalf D., Coleman M. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N. Engl. J. Med. 1992, 327(9):604-612.
64. Sigmundsson T., Maier M., Toone B.K., Williams S.C., Simmons A., Greenwood K., Ron M.A. Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr. Res. 2003, 64(1):63-71.
65. Stanley J., Vemulapalli M., Nutche J., Montrose D.M., Sweeney J.A., Pettegrew J.W., MacMaster F.P., Keshavan M.S. Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel 1H spectroscopy study. Schizophr. Res. 2007, 93(1-3):23-32.
66. Steen R., Hamer R., Lieberman J. Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005, 30(11):1949-1962.
67. Szulc A., Galinska B., Tarasow E., Dzienis W., Kubas B., Konarzewska B., Walecki J., Alathiaki A.S., Czernikiewicz A. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry 2005, 38(5):214-219.
68. Taylor J., Blanton R., Levitt J., Caplan R., Nobel D., Toga A. Superior temporal gyrus differences in childhood-onset schizophrenia. Schizophr. Res. 2005, 73(2-3):235-241.
69. Thomas M.A., Ke Y., Levitt J., Caplan R., Curran J., Asarnow R., McCracken J. Preliminary study of frontal lobe 1H MR spectroscopy in childhood-onset schizophrenia. J. Magn. Reson. Imaging 1998, 8(4):841-846.
70. Tibbo P., Hanstock C., Valiakalayil A., Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am. J. Psychiatry 2004, 161(6):1116-1118.
71. Tsien J. Linking Hebb's coincidence-detection to memory formation. Curr. Opin. Neurobiol. 2000, 10(2):266-273.
72. Urenjak J., Williams S., Gadian D., Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J. Neurosci. 1993, 13(3):981-989.
73. van Berckel B., Bossong M., Boellaard R., Kloet R., Schuitemaker A., Caspers E., Luurtsema G., Windhorst A., Cahn W., Lammertsma A., Kahn R. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[(11)C]PK11195 positron emission tomography study. Biol. Psychiatry 2008, 64(9):820-822.
74. Wechsler D. Manual for the Wechsler Intelligence Scale for Children, Revised 1974, Psychological Corp, New York.
75. Westbrook G., Mayer M., Namboodiri M., Neale J. High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture. J. Neurosci. 1986, 6(11):3385-3392.
76. Willis-Shore J., Poole J., Skinner H., Benioff L., Vinogradov S. Two commonly used indices of thought disorder. Schizophr. Res. 2000, 42(3):261-262.
77. Wood S.J., Berger G., Velakoulis D., Phillips L.J., McGorry P.D., Yung A.R., Desmond P., Pantelis C. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr. Bull. 2003, 29(4):831-843.
78. Wood S., Berger G., Lambert M., Conus P., Velakoulis D., Stuart G., Desmond P., McGorry P., Pantelis C. Prediction of functional outcome 18months after a first psychotic episode: a proton magnetic resonance spectroscopy study. Arch. Gen. Psychiatry 2006, 63(9):969-976.
79. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
80. Yamasue H., Fukui T., Fukuda R., Yamada H., Yamasaki S., Kuroki N., Abe O., Kasai K., Tsujii K., Iwanami A., Aoki S., Ohtomo K., Kato N., Kato T. 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. Neuroreport 2002, 13(16):2133-2137.
81. Yasukawa R., Miyaoka T., Mizuno S., Inagaki T., Horiguchi J., Oda K., Kitagaki H. Proton magnetic resonance spectroscopy of the anterior cingulate gyrus, insular cortex and thalamus in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). J. Psychiatry Neurosci. 2005, 30(6):416-422.
82. Zabala A., Sanchez-Gonzalez J., Parellada M., Moreno D., Reig S., Burdalo M., Robles O., Desco M., Arango C. Findings of proton magnetic resonance spectometry in the dorsolateral prefrontal cortex in adolescents with first episodes of psychosis. Psychiatry Res. 2007, 156(1):33-42.